ProCE Banner Activity

ExpressPoints
Staying on TRK: Addressing Clinical Challenges and Improving Outcomes in NTRK Fusion–Positive Cancers

Slideset Download
Download these expert-selected slides with the latest information on testing for TRK fusions and treating your patients with NTRK fusion-positive cancers.

Released: June 16, 2021

Expiration: June 15, 2022

No longer available for credit.

Share

Faculty

George D. Demetri

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Theodore Laetsch

Theodore Laetsch, MD

Associate Professor
Division of Oncology
Department of Pediatrics
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Theodore Laetsch, MD

Associate Professor
Division of Oncology
Department of Pediatrics
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania